Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.

Trial Details

NCT ID
NCT06365788
Phase
PHASE2
Sponsor
Universitaire Ziekenhuizen KU Leuven
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Abemaciclib
  • Bicalutamide
Locations (sample)
  • Antwerp, Belgium|51.22047,4.40026
  • Antwerp, Belgium|51.22047,4.40026
  • Brussels, Belgium|50.85045,4.34878
  • Ghent, Belgium|51.05,3.71667
  • Hasselt, Belgium|50.93106,5.33781

Key Eligibility Criteria

  • Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analysis. If a patient declines to par…
  • Women aged at least 18 years
  • The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic AR+ TNBC
  • AR+ assessed locally and defined as ≥1% of cells staining on IHC of last recurrent/metastatic breast cancer specimen

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →